148 related articles for article (PubMed ID: 3098444)
41. Hexamethylmelamine: a critical review of an active drug.
Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
[TBL] [Abstract][Full Text] [Related]
42. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
43. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
44. The curative action of hexamethylmelamine on intramuscularly or intracerebrally implanted Yoshida sarcoma.
Osswald H
Cancer Lett; 1984 Jan; 21(3):343-9. PubMed ID: 6420045
[TBL] [Abstract][Full Text] [Related]
45. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro.
Jackson C; Hartley JA; Jenkins TC; Godfrey R; Saunders R; Thurston DE
Biochem Pharmacol; 1991 Nov; 42(11):2091-7. PubMed ID: 1958227
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
47. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
[TBL] [Abstract][Full Text] [Related]
48. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
[TBL] [Abstract][Full Text] [Related]
49. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
50. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.
Rutty CJ; Newell DR; Muindi JR; Harrap KR
Cancer Chemother Pharmacol; 1982; 8(1):105-11. PubMed ID: 6807560
[TBL] [Abstract][Full Text] [Related]
51. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G
Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893
[TBL] [Abstract][Full Text] [Related]
52. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
Hauge MD; Long HJ; Hartmann LC; Edmonson JH; Webb MJ; Su J
Invest New Drugs; 1992 Nov; 10(4):299-301. PubMed ID: 1487403
[TBL] [Abstract][Full Text] [Related]
54. Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
Smith JP; Rutledge FN
Natl Cancer Inst Monogr; 1975 Oct; 42():169-72. PubMed ID: 825778
[TBL] [Abstract][Full Text] [Related]
55. Toxicity and antitumor activity of hexamethylmelamine and its N-demethylated metabolites in mice with transplantable tumors.
Lake LM; Grunden EE; Johnson BM
Cancer Res; 1975 Oct; 35(10):2858-63. PubMed ID: 808270
[TBL] [Abstract][Full Text] [Related]
56. In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice.
Garattini E; Donelli MG; Colombo T; Paesani R; Pantarotto C
Biochem Pharmacol; 1981 May; 30(10):1151-4. PubMed ID: 6789835
[No Abstract] [Full Text] [Related]
57. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Keldsen N; Havsteen H; Vergote I; Bertelsen K; Jakobsen A
Gynecol Oncol; 2003 Feb; 88(2):118-22. PubMed ID: 12586589
[TBL] [Abstract][Full Text] [Related]
58. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
59. Growth inhibition of human tumor xenografts in nude mice by treatment with the antitumor agent 4,6-benzylidene-d1-D-glucose (P-1013).
Dunsaed CB; Dornish JM; Aastveit TE; Nesland JM; Pettersen EO
Anticancer Drugs; 1995 Jun; 6(3):456-64. PubMed ID: 7670145
[TBL] [Abstract][Full Text] [Related]
60. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
